Arena reports results of APD916 Look 1 clinical enquiry championing narcolepsy with cataplexy

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today results from a Step 1 clinical hearing of APD916, a unusual cure applicant discovered close Arena that targets the histamine H3 receptor for the treatment of narcolepsy with cataplexy.

The randomized, double-blind and placebo-controlled hardship evaluated the shelter, tolerability and pharmacokinetics of 1 mg, 3 mg and 5 mg pick doses of APD916. The buy cheap Desogen shot evaluated 24 wholesome volunteers in three cohorts of eight participants each, six randomized to APD916 and two to placebo. APD916 demonstrated dose-proportional pharmacokinetic airing in the tested dose range. The fatal half-life was approximately 50 hours.

Dose-limiting CNS adverse events occurred at the 5 mg dose, including insomnia, offbeat dreams and a nightmare. Adverse events of insomnia, nausea, annoyance, parosmia, alterations in perception of consistency temperat ure, queer dreams and visual and tactile hallucinations were commonly reported at the 3 mg and 5 mg doses, and adverse events of insomnia were commonly reported at the 1 mg dose. All adverse events in the distress were indulgent or lessen in nature. No buy revatio online grim adverse events were reported nor were there any consequential protection issues with respect to central signs, ECGs or laboratory testing.

APD916 is a well compelling formulate, and we believe that exposures of 1 mg or less could be sufficient for the intended sedulous citizenry, said William R. Shanahan, M.D., Arena's Older Vice President and Chief Medical Officer. We are currently evaluating next steps for this program.